PMC:7212965 / 89725-90182 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T220","span":{"begin":226,"end":231},"obj":"Body_part"},{"id":"T221","span":{"begin":249,"end":254},"obj":"Body_part"}],"attributes":[{"id":"A220","pred":"fma_id","subj":"T220","obj":"http://purl.org/sig/ont/fma/fma7197"},{"id":"A221","pred":"fma_id","subj":"T221","obj":"http://purl.org/sig/ont/fma/fma7197"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T182","span":{"begin":226,"end":231},"obj":"Body_part"},{"id":"T183","span":{"begin":249,"end":254},"obj":"Body_part"}],"attributes":[{"id":"A182","pred":"uberon_id","subj":"T182","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"A183","pred":"uberon_id","subj":"T183","obj":"http://purl.obolibrary.org/obo/UBERON_0002107"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T418","span":{"begin":36,"end":46},"obj":"Disease"},{"id":"T419","span":{"begin":172,"end":180},"obj":"Disease"}],"attributes":[{"id":"A418","pred":"mondo_id","subj":"T418","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A419","pred":"mondo_id","subj":"T419","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T706","span":{"begin":160,"end":167},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T707","span":{"begin":199,"end":201},"obj":"http://purl.obolibrary.org/obo/CLO_0001302"},{"id":"T708","span":{"begin":226,"end":231},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T709","span":{"begin":226,"end":231},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"},{"id":"T710","span":{"begin":249,"end":254},"obj":"http://purl.obolibrary.org/obo/UBERON_0002107"},{"id":"T711","span":{"begin":249,"end":254},"obj":"http://www.ebi.ac.uk/efo/EFO_0000887"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T219","span":{"begin":106,"end":108},"obj":"Chemical"},{"id":"T220","span":{"begin":280,"end":282},"obj":"Chemical"},{"id":"T221","span":{"begin":283,"end":285},"obj":"Chemical"},{"id":"T222","span":{"begin":315,"end":317},"obj":"Chemical"},{"id":"T223","span":{"begin":431,"end":434},"obj":"Chemical"},{"id":"T224","span":{"begin":445,"end":454},"obj":"Chemical"},{"id":"T225","span":{"begin":455,"end":457},"obj":"Chemical"}],"attributes":[{"id":"A219","pred":"chebi_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A220","pred":"chebi_id","subj":"T220","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"},{"id":"A221","pred":"chebi_id","subj":"T221","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A222","pred":"chebi_id","subj":"T222","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A223","pred":"chebi_id","subj":"T223","obj":"http://purl.obolibrary.org/obo/CHEBI_76649"},{"id":"A224","pred":"chebi_id","subj":"T224","obj":"http://purl.obolibrary.org/obo/CHEBI_16990"},{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_145751"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}

{"project":"LitCovid-sentences","denotations":[{"id":"T880","span":{"begin":0,"end":70},"obj":"Sentence"},{"id":"T881","span":{"begin":71,"end":137},"obj":"Sentence"},{"id":"T882","span":{"begin":138,"end":185},"obj":"Sentence"},{"id":"T883","span":{"begin":186,"end":211},"obj":"Sentence"},{"id":"T884","span":{"begin":212,"end":246},"obj":"Sentence"},{"id":"T885","span":{"begin":247,"end":295},"obj":"Sentence"},{"id":"T886","span":{"begin":296,"end":404},"obj":"Sentence"},{"id":"T887","span":{"begin":405,"end":457},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2190","span":{"begin":315,"end":317},"obj":"Gene"},{"id":"2191","span":{"begin":283,"end":285},"obj":"Gene"},{"id":"2285","span":{"begin":138,"end":146},"obj":"Species"},{"id":"2307","span":{"begin":445,"end":454},"obj":"Chemical"}],"attributes":[{"id":"A2190","pred":"tao:has_database_id","subj":"2190","obj":"Gene:2770"},{"id":"A2191","pred":"tao:has_database_id","subj":"2191","obj":"Gene:2770"},{"id":"A2285","pred":"tao:has_database_id","subj":"2285","obj":"Tax:9606"},{"id":"A2307","pred":"tao:has_database_id","subj":"2307","obj":"MESH:D001663"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":" Sun, 202039The National Centre for Infectious DiseasesSingaporeDates: 1/26/2020-2/16/2020Last follow-up: NR n = 54Survival: NRInclusion: Patients referred for testing for COVID-19.Age: M 42 y (IQR, 34–54 y)Sex: 46% femalesGI/liver comorbidities: 0 liver diseaseDisease severity: NR GI symptoms: 37% (20/54)General GI symptoms per different models were associated with positive COVID adjusted odds ratio. 3.73 (95% CI, 1.23–12.45) AST, ALT, and bilirubin NR"}